How is Bevacizumab intravenous route dosed?
Bevacizumab intravenous route is dosed based on the patient's weight and medical condition. The usual dose for treating various types of cancer is 5 to 15 milligrams (mg) per kilogram (kg) of body weight, administered intravenously (into a vein) every 3 to 6 weeks, along with other medications. The exact dose and dosing schedule should be determined by a healthcare professional, such as an oncologist, based on the patient's individual needs and response to treatment.
What is the dosage form of Bevacizumab intravenous route?
The dosage forms of bevacizumab intravenous route are solution.
How is Bevacizumab intravenous route administered?
Bevacizumab intravenous route is given through injection by a healthcare professional, typically in a hospital or clinical setting. It is not meant for self-administration.
What are common precautions when taking Bevacizumab intravenous route?
Common precautions when taking bevacizumab intravenous route include:
- Informing healthcare providers: Ensure that all doctors, dentists, and healthcare providers who treat you are aware that you are receiving bevacizumab. You may need to stop receiving it at least 28 days before or after having surgery and until the wound has healed enough.
- Monitoring for infections: Bevacizumab can temporarily lower the number of white blood cells, increasing the risk of infections. Avoid people with infections, and seek immediate medical attention if you experience symptoms such as fever, chills, cough, or difficulty breathing.
- Blood pressure monitoring: Bevacizumab may cause an increase in blood pressure. Your healthcare provider should monitor your blood pressure during treatment and adjust medications as needed.
- Kidney function: The medicine can potentially cause serious kidney problems. Inform your doctor if you have a history of kidney disease, and report any symptoms such as blood in the urine, decreased urine output, swelling in the face or lower legs, or difficulty breathing.
- Infusion-related reactions: Bevacizumab may cause infusion-related reactions, which can be life-threatening. Inform your healthcare provider immediately if you experience fever, chills, dizziness, trouble breathing, itching, rash, or other concerning symptoms during the infusion.
- Heart failure: Do not receive bevacizumab together with cancer medicines containing anthracycline if you have heart failure. Consult your doctor for further guidance. Always follow your healthcare provider's instructions and report any side effects or concerns promptly.